FDA Approves Simtriyo As ADHD Medication

On July 24, 2026, the U.S. Food and Drug Administration (FDA) approved a new type of medication for attention-deficit/hyperactivity disorder (ADHD). The medication, called Simtriyo® (centanafadine) and developed by Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka), is the first and only approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD and introduces a new treatment approach for the condition. It is expected to be commercially available later in 2026 following scheduling by the U.S. Drug Enforcement Administration (DEA).

Simtriyo inhibits the reuptake of three neurotransmitters, norepinephrine, dopamine, and serotonin, and is . . .